Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Tauopathies 2Neurodegenerative Diseases 2Nervous System Diseases 2Mental Disorders 2Inflammation 2Dementia 2Central Nervous System Diseases 2Brain Diseases 2Alzheimer Disease 2Neurocognitive Disorders 1Cognitive Dysfunction 1

Interventions

Exercise 5Vitamin D 3Resistance Training 3Omeprazole 3Etanercept 3Dexmedetomidine 3Ascorbic Acid 3salicylsalicylic acid 2palbociclib 2epigallocatechin gallate 2XENP 1595 2Tea 2Tablets 2Surgical Procedures, Operative 2Sufentanil 2Spironolactone 2Probiotics 2Pioglitazone 2Oxycodone 2Nutrition Assessment 2Morphine 2Metformin 2Ketorolac 2Infliximab 2Ibuprofen 2Fish Oils 2Endurance Training 2Colchicine 2Blood Specimen Collection 2Aspirin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Inflammation × XENP 1595 × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡